GB0608806D0 - Combination therapy product and uses thereof - Google Patents

Combination therapy product and uses thereof

Info

Publication number
GB0608806D0
GB0608806D0 GBGB0608806.6A GB0608806A GB0608806D0 GB 0608806 D0 GB0608806 D0 GB 0608806D0 GB 0608806 A GB0608806 A GB 0608806A GB 0608806 D0 GB0608806 D0 GB 0608806D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy product
product
combination
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0608806.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipopeptide AB
Original Assignee
Lipopeptide AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipopeptide AB filed Critical Lipopeptide AB
Priority to GBGB0608806.6A priority Critical patent/GB0608806D0/en
Publication of GB0608806D0 publication Critical patent/GB0608806D0/en
Priority to EP07732700A priority patent/EP2012823A2/en
Priority to JP2009508475A priority patent/JP2009535392A/en
Priority to AU2007251362A priority patent/AU2007251362A1/en
Priority to CA002651067A priority patent/CA2651067A1/en
Priority to CNA2007800235556A priority patent/CN101478988A/en
Priority to PCT/GB2007/001671 priority patent/WO2007132178A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0608806.6A 2006-05-04 2006-05-04 Combination therapy product and uses thereof Ceased GB0608806D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0608806.6A GB0608806D0 (en) 2006-05-04 2006-05-04 Combination therapy product and uses thereof
EP07732700A EP2012823A2 (en) 2006-05-04 2007-05-04 Combination therapy product and uses thereof
JP2009508475A JP2009535392A (en) 2006-05-04 2007-05-04 Combination therapy products and their use
AU2007251362A AU2007251362A1 (en) 2006-05-04 2007-05-04 Combination therapy product and uses thereof
CA002651067A CA2651067A1 (en) 2006-05-04 2007-05-04 Combination therapy product and uses thereof
CNA2007800235556A CN101478988A (en) 2006-05-04 2007-05-04 Combination therapy product and uses thereof
PCT/GB2007/001671 WO2007132178A2 (en) 2006-05-04 2007-05-04 Combination therapy product and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0608806.6A GB0608806D0 (en) 2006-05-04 2006-05-04 Combination therapy product and uses thereof

Publications (1)

Publication Number Publication Date
GB0608806D0 true GB0608806D0 (en) 2006-06-14

Family

ID=36603903

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0608806.6A Ceased GB0608806D0 (en) 2006-05-04 2006-05-04 Combination therapy product and uses thereof

Country Status (7)

Country Link
EP (1) EP2012823A2 (en)
JP (1) JP2009535392A (en)
CN (1) CN101478988A (en)
AU (1) AU2007251362A1 (en)
CA (1) CA2651067A1 (en)
GB (1) GB0608806D0 (en)
WO (1) WO2007132178A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
DE19935771A1 (en) * 1999-07-23 2001-02-01 Schering Ag New vitamin D derivatives with cyclic substructures in the side chains, processes and intermediates for their manufacture and their use in the manufacture of pharmaceuticals
US7361664B2 (en) * 2001-06-20 2008-04-22 The United States Of America As Represented By The Department Of Health And Human Services Vitamin D receptor antagonists and related compositions and methods of use
JP2006514106A (en) * 2002-12-19 2006-04-27 ヒルマン，イチャク Disease treatment with antibacterial peptide inhibitors

Also Published As

Publication number Publication date
WO2007132178A2 (en) 2007-11-22
AU2007251362A1 (en) 2007-11-22
WO2007132178A3 (en) 2008-02-07
CA2651067A1 (en) 2007-11-22
CN101478988A (en) 2009-07-08
EP2012823A2 (en) 2009-01-14
JP2009535392A (en) 2009-10-01

Similar Documents

Publication Publication Date Title
GB0625659D0 (en) Therapeutic compounds and their use
TWI561237B (en) Substituted dihydropyrazolones and their use
ZA200810323B (en) Fkbp-l and uses thereof
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
IL194751A0 (en) Drugs and uses
PL2064327T3 (en) Dbait and uses thereof
HK1136819A1 (en) Novel dithiolopyrrolones and their therapeutic applications
EP2054061A4 (en) Combination therapy
HK1133552A1 (en) Carboranylporphyrins and uses thereof
PL2012805T3 (en) Therapeutic composition and use
GB0607946D0 (en) Mono and combination therapy
GB0607949D0 (en) Mono and combination therapy
EP2076239A4 (en) Combination therapy
EP2097085A4 (en) Therapeutic materials and methods
EP1942911A4 (en) Therapeutic molecules and their uses
GB0701728D0 (en) Assays and therapy
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB0608806D0 (en) Combination therapy product and uses thereof
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB0625633D0 (en) Therapeutic compounds and their use
GB2444960B (en) Combined pseudoscope and hyperscope
GB0711465D0 (en) Silan-3-amines and disilan-5-amines as therapeutic agents
AU2007902930A0 (en) Therapeutic agents and uses therefor
GB0722338D0 (en) Novel use and treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)